Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Free Research Reports on BGMD, MCP, RSH and THLD Issued by the Bedford Report

BGMD, MTEM
Free Research Reports on BGMD, MCP, RSH and THLD Issued by the Bedford Report
http://media.marketwire.com/attachments/201211/53317_equitynewscircuit-logo-final.jpghttp://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=978766&ProfileId=051205&sourceType=1

NEW YORK, NY -- (Marketwire) -- 01/28/13 -- The Bedford Report has released new equity reports today. As a leading provider of free in depth reports and timely market updates, Bedford is an essential resource for hundreds of thousands of investors across the country.

BG Medicine, Inc. (NASDAQ: BGMD) shares plunged 15 percent on nearly 3 million shares traded Friday. The company earlier this month announced it has obtained a CE Mark for its first automated version of the BGM Galectin-3 blood test.

Find out more about BG Medicine including full access to the free equity report at: www.BedfordReport.com/BGMD

Molycorp Inc. (NYSE: MCP) shares of the rare earth miner rallied 13 percent on over 51 million shares traded Friday, which was nearly five-times the average daily volume. The company anticipates lower than expected revenue and cash flow for 2013. Molycorp is scheduled to release its fourth quarter results on February 18th.

Find out more about Molycorp including full access to the free equity report at: www.BedfordReport.com/MCP

RadioShack Corporation (NYSE: RSH) surged 14.3 percent on over 5.5 million shares traded Friday. Last week, Zacks upgraded the company's rating to "neutral" from "underperform." Shares of RadioShack have plunged nearly 75 percent in the past year.

Find out more about RadioShack including full access to the free equity report at: www.BedfordReport.com/RSH

Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) is focused on the discovery and development of drugs targeting tumor hypoxia. Threshold's partner, Merck KGaA, recently initiated a global Phase 3 MAESTRO study of TH-302, triggering a $30 million milestone payment.

Find out more about Threshold Pharmaceuticals including full access to the free equity report at: www.BedfordReport.com/THLD

Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein.

A third party, Providence Media Strategies LLC has paid Equity News Circuit four hundred and fifty dollars for the publication of this news release. Neither Equity News Circuit, nor the hiring party, has a financial relationship with any company whose stock is mentioned in this release. Neither Equity News Circuit nor the hiring party are a registered investment advisor, and nothing in this report is intended as a solicitation to buy or sell any security.

Contact Information:

Equity News Circuit
Email Contact



Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today